Concepedia

Jens Stechl

JS

5

Publications

177

Citations

5

H-Index

1989

Active since

Affiliations

Klinikum Frankfurt Höchst(Current)

Sanofi (France)

Sanofi (Germany)

Jens Stechl is an author at Klinikum Frankfurt Höchst specializing in medicine, pharmacology, and pharmacotherapy.

Top concepts

Publications per year

1989–2015

5

Publications

5

DesArg9D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin (desArg10-[Hoe140]) is a bradykinin B1 receptor antagonist

Klaus Wirth, Gerhard Breipohl, Jens Stechl et al. · European Journal of Pharmacology · 1991 · 76 citations

, , +7

Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects

R. H. A. Becker, Jens Stechl, A. Steinstraesser et al. · Diabetes/Metabolism Research and Reviews · 2015 · 46 citations · Full text

Lixisenatide resensitizes the insulin‐secretory response to intravenous glucose challenge in people with type 2 diabetes – a study in both people with type 2 diabetes and healthy subjects

R. H. A. Becker, Jens Stechl, Jérôme Msihid et al. · Diabetes Obesity and Metabolism · 2014 · 26 citations · Full text

Effects of the novel compound, Hoe 065, upon impaired learning and memory in rodents

Franz J. Hock, Hermann J. Gerhards, Gabriele Wiemer et al. · European Journal of Pharmacology · 1989 · 15 citations

, , +9

Effects of Hoe 065, a compound structurally related to inhibitors of angiotensin converting enzyme, on acetylcholine metabolism in rat brain

Gabriele Wiemer, R. H. A. Becker, Hermann J. Gerhards et al. · European Journal of Pharmacology · 1989 · 14 citations

, , +10

Rows per page

1–5 of 5